title: Frequent occurrence of parvovirus B19 DNAemia in the first year after kidney transplantation.
abstract: Described for the first time in 1986, Parvovirus B19 (B19V) infection in kidney transplant recipients remains little-known and probably underestimated. The aims of this study were to establish B19V infection frequency during the first year after kidney transplant and to determine predisposing factors and manifestations of the infection in renal transplant recipients. Sixty consecutive adult patients, transplanted less than a year before, were included in this study. B19V and other opportunistic viral infections were detected retrospectively in plasma samples collected every 15 days during the first 3 months and every month from 3 months to 1 year following the kidney transplant. Demographic characteristics, immunosuppressive treatment and biological findings were recorded on each sampling date. Six patients (10%) presented B19V viremia, while eight CMV (13.3%), seven EBV (11.7%), five HHV-6 (8.3%), five BKV (8.3%), and two adenovirus (3.3%) infections were detected. The mean value of B19V viral load was 149 UI/ml. B19V infections were either reactivation or reinfection due to genotype two in five cases, while one case of primary infection with genotype 1 was observed. Neither risk factors nor biological consequences of B19V infection have been identified. These results rank B19V third among opportunistic viral infections occurring during the first year after a kidney transplant. With regard to this high incidence, and even if the risk factors and biological consequences of the infection should be assessed in larger studies, the question of systematic screening and follow-up of B19V infection in kidney transplant recipients is relevant.
authors.affiliation: Clinical and Molecular Virology Unit, University Hospital and EA-4684 Cardiovir SFR-CAP santé, Faculty of Medicine, Reims, France.
authors.forename: Roseline
authors.initials: R
authors.lastname: Porignaux
authors.forename: Vincent
authors.initials: V
authors.lastname: Vuiblet
authors.forename: Coralie
authors.initials: C
authors.lastname: Barbe
authors.forename: Yohan
authors.initials: Y
authors.lastname: Nguyen
authors.forename: Sylvie
authors.initials: S
authors.lastname: Lavaud
authors.forename: Olivier
authors.initials: O
authors.lastname: Toupance
authors.forename: Laurent
authors.initials: L
authors.lastname: Andréoletti
authors.forename: Philippe
authors.initials: P
authors.lastname: Rieu
authors.forename: Nicolas
authors.initials: N
authors.lastname: Lévêque
mesh_terms: D000328:Adult; D003587:Cytomegalovirus / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D004279:DNA, Viral / Q000097:blood*; D020031:Epstein-Barr Virus Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D005260:Female; D005602:France / Q000453:epidemiology; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D012189:Retrospective Studies; D019562:Viral Load; D014766:Viremia / Q000097:blood / Q000453:epidemiology / Q000276:immunology* / Q000821:virology
chemical_list: D004279:DNA, Viral